Detalle Publicación

ARTÍCULO
Bivalent Therapeutic Vaccine Against HPV16/18 Genotypes Consisting of a Fusion Protein Between the Extra Domain A From Human Fibronectin and HPV16/18 E7 Viral Antigens
Autores: Arribillaga Arangoa, Laura; Echeverria, Iciar; Belsue V; Gomez T; Lozano Moreda, Teresa; Casares Lagar, Noelia; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervas Stubbs, Sandra; Sarobe Ugarriza, Pablo; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte Sagastibelza, Juan José (Autor de correspondencia)
Título de la revista: JOURNAL FOR IMMUNOTHERAPY OF CANCER
ISSN: 2051-1426
Volumen: 8
Número: 1
Fecha de publicación: 2020
Lugar: WOS
Resumen:
Background In vivo targeting of human papillomavirus (HPV) derived antigens to dendritic cells might constitute an efficient immunotherapeutic strategy against cervical cancer. In previous works, we have shown that the extra domain A from murine fibronectin (mEDA) can be used to target antigens to toll-like receptor 4 (TLR4) expressing dendritic cells and induce strong antigen-specific immune responses. In the present study, we have produced a bivalent therapeutic vaccine candidate consisting of the human EDA (hEDA) fused to E7 proteins from HPV16 and HPV18 (hEDA-HPVE7-16/18) and evaluate its potential as a therapeutic vaccine against cervical cancer. Materials and methods Recombinant fusion proteins containing HPV E7 proteins from HPV16 and HPV18 virus subtypes fused to hEDA were produced and tested in vitro on their capacity to bind TLR4 and induce the production of tumor necrosis factor-alpha or interleukin (IL)-12 by human monocytes and dendritic cells. The immunogenicity and potential therapeutic activity of the vaccine in combination with cisplatin or with the TLR3 agonist molecules polyinosinic-polycytidylic acid (Poly IC) or Poly ICLC was evaluated in mice bearing subcutaneous or genital orthotopic HPV16 TC-1 tumors. Results hEDA-HPVE7-16/18 prototype vaccine binds human TLR4 and stimulate TLR4-dependent signaling pathways and IL-12 production by human monocyte-derived dendritic cell. Vaccination with hEDA-HPVE7-16/18 induced strong HPVE7-specific Cytotoxic T lymphocy